Drugs / Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05431725 | Jul 2022 → Jul 2023 | influenza | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT06824519 Comparator | May → Aug 2025 overdue | influenza | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05642078 Comparator | Feb 2023 → Jan 2024 | — | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Influenza Vaccine(Split Virion),Inactivated Quadrivalent | “Influenza Vaccine(Split Virion),Inactivated Quadrivalent,Produced by Hualan Biological Vaccine Co., Ltd.;0.25mL/branch,each contains 7.5 μg H1N1, H3N2, B(V), B(Y) hemagglutinin.” NCT05642078 ↗ |
| Modality | Vaccine | “The influenza vaccines (Split Virion), inactivated, quadrivalent are developed by Sinovac Biotech Co., Ltd.” NCT05431725 ↗ |
| Route | Intramuscular | “The routine of administration is intramuscular injection into deltoid region.” NCT05431725 ↗ |